Michele Evans’ Post

Thoughts on this? >> Kazia prunes failed brain cancer trial data set to manufacture path to FDA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharmaceutical #pharma #biotech

Thoughts on this? >> Kazia prunes failed brain cancer trial data set to manufacture path to FDA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #pharma #healthcare #biotech

🔬 Happy Friday everyone, before we head off for the weekend its time for our next LSX USA Congress Biotech company showcase. Todays company Lisata Therapeutics, Inc. ⭐ Lisata Therapeutics, which was formed from the merger of Caladrius Biosciences and Cend Therapeutics, is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, certepetide, is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. Certepetide actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. Certepetide has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of certepetide to enable a variety of treatment modalities to treat a range of solid tumors more effectively. 🌟 Lisata is another long time attendee of ours and always gives a great presentation. We look forward to hearing from you again David J. Mazzo, Ph.D. and John Menditto #lsxusa #investment #biotech #pharma #immunotherpies #rna

Thoughts on this? >> Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #competitivemarketing #healthcare

Thoughts on this? >> Foresee Pharmaceuticals Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer >> Comment below! >>> lqventures.com #IoT #industry40 #healthtech #AI #mhealth

🔬 Advancing Anticancer Research: De Novo Design of Hypoxanthine Analogues Against A549 Cell Line Thrilled to share insights from our final year B. Pharmacy project, where we explored the de novo design and synthesis of hypoxanthine analogues with promising anticancer activity. Our team synthesized various compounds and tested their efficacy on A549 (lung carcinoma) cells using the MTT assay, which measures cell viability as a marker of cytotoxicity. 🧪 Key Findings: Using different concentrations (400 to 12.5 µg/ml), we observed that several of our compounds exhibited remarkable potency. The IC50 values (concentration required to inhibit cell growth by 50%) ranged from 31.05 to 72.31 µg/ml. Here are some highlights: • HSPN-6: Showed the highest potency with an IC50 of 31.05 µg/ml. • HSPN-5: Demonstrated an IC50 of 39.12 µg/ml. • Both HSPN-6 and HSPN-5 surpassed the activity of the standard drug 6-Mercaptopurine (IC50 = 36.12 µg/ml), suggesting greater efficacy in inhibiting cancer cell growth. I extend my heartfelt gratitude to my guide, Dr. Pramod Sir, for his invaluable support and mentorship throughout this journey. This project has inspired me to contribute further to oncology research and pharmaceutical development. Stay tuned – I’ll be sharing our full research article in the coming days! #AnticancerResearch #PharmacyStudents #DeNovoDesign #HypoxanthineAnalogues #A549 #MTTAssay #DrugDiscovery #OncologyResearch #Pharmaceuticals #ResearchAndDevelopment

#MovingMedicineForward: Discover how this partnership will enhance our support for #Oncology #DrugDevelopment - read the full article here:

Exciting developments at the 42nd annual J.P. Morgan Healthcare Conference! GSK has joined the ranks of industry leaders in the dealmaking frenzy. Notably, J&J committed $2 billion to acquire Ambrx, specializing in antibody-drug conjugates for cancer. Merck followed suit with a $680 million investment in Harpoon Therapeutics for T-cell engagers in oncology. Meanwhile, Novartis made strategic moves, including a $250 million buyout of Calypso Biotech to enhance its presence in immune diseases. Additionally, two RNAi license deals with Shanghai Argo Biopharmaceutical are set to advance cardiovascular indications. The healthcare landscape is evolving, and it's inspiring to witness these impactful collaborations! #HealthcareInnovation #IndustryLeaders #DealMaking #JPMorganConference #lifescience

If your interested at all, here are some recent pharma updates: Cytokinetics: announced that recent study hit not only the primary endpoint, but all pre-specified endpoints (They plan to submit for NDA late 2024) Deciphera Pharmaceuticals: ONO Pharmaceuticals will acquire Deciphera for $2.4 billion ADC Therapeutics: shared positive topline data from a Phase 2 cancer trial for drug Zynlonta and has announced a $105 million offering Eli Lilly and Company: announced they will face questions from a panel of Alzheimer's experts on June 10, setting up approval decision for Donanemab They also announced that Mazdutide (GLP-1) was superior compared with older Lilly drug Dulaglutide Merck Healthcare: to wind down phase 3 study due to safety related dropouts of Anti-TIGIT drug Vibostolimab in skin cancer #pharmaupdates #pharmaceuticalupdates #industryupdates #biotechupdates #biotechnologyupdates #thisweekinpharma

Big news in lung cancer treatment! 🎉 Bristol Myers Squibb's Krazati has shown promising results in the Phase III KRYSTAL-12 study. This innovative drug is designed for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors the KRAS G12C mutation. 🧬The study revealed that Krazati significantly improves progression-free survival (PFS) compared to standard-of-care chemotherapy, specifically in the second-line setting or later. It also demonstrated a better overall response rate, with a safety profile consistent with previous trials. 📊Krazati, originally developed by Mirati, is a game-changer as it locks the mutant KRAS G12C protein in its inactive state, blocking its downstream signaling without affecting healthy cells. 🛡️This advancement is particularly crucial for patients who have undergone at least one prior line of systemic therapy. With Krazati's FDA approval in December 2022 and the positive results from KRYSTAL-12, BMS is now ahead of the game in the KRAS inhibitor space, especially after Amgen's recent setback with Lumakras. 🚀Stay tuned for more updates as BMS plans to share the full analysis at an upcoming medical congress and submit the data to health authorities. #Oncology #LungCancer #Krazati #KRASG12C #NSCLC #BristolMyersSquibb #CancerResearch #ClinicalTrials #PharmaNews #MedicalInnovation"